Exabis Library
Welcome to the e-CCO Library!
P101 Biomarkers of elastin degradation are associated with clinical and biochemically active disease in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P101: Circulating MicroRNA-16 in Inflammatory Bowel Disease Patients - Potential Biomarker to Assess Inflammation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P101: Fecal calprotectin is increased among patients with pouchitis and increases with increasing endoscopic subscores: Real-world data from a prospectively collected database
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P101: Functional translation of IBD-associated genetic variation in patient-derived intestinal epithelial cells
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P101: Innate immunity and Crohn’s disease recurrence after surgery
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P101: Interleukin-13 induces polarity defects in the intestinal epithelia
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P101: Isosteviol Attenuates Dextran Sulfate Sodium-Induced Colitis by Maintaining the Intestinal Barrier Through PDK1/AKT/NF-κB Signaling
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P101: Simple five-point classification of MR enterocolonography for Crohn’s disease based on enteroscopic findings
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P102 Host gene background and concentration influence the butyrate effect on modulating IECs proliferation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P102: α-Defensins(αDef) 1-3 are specific plasmatic markers for Crohn’s disease (CD) at diagnosis and tissue α-Def 5 methylation is a pathogenic mechanism for αDef-5 down regulation in CD.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P102: A small molecule selective integrin α4β7 inhibitor demonstrates efficacy in a chronic model of Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P102: Changes in serum immune protein profiles following vedolizumab therapy in Inflammatory Bowel Disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P102: Hypoxia reduces inflammation through the downregulation of NLRP3/mTOR signaling and the activation of autophagy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P102: Increased abundance of gut microbial virulence genes and pro-inflammatory pathways during Crohn’s disease exacerbations
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P102: Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P102: Subclinical atherosclerosis assessed by coronary artery calcium score in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P103 The treatment effect of tonsil-derived mesenchymal stem cells (T-MSCs) via regulating programmed death-1/programmed death ligand-1 (PD-1/PD-L1) in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P103: Colitis-associated faecal miRNAs are mediators of host-microbiota interactions and key regulators of intestinal permeability and inflammation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P103: Degradation and formation of type III, IV and V collagen are associated with disease activity, disease severity and disease extension in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P103: Evaluation of efficacy of new vectors for siRNA CYCLIN D1 and E2F1 delivery in control of cancer progression in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM